Rutgers Cancer Institute of New Jersey Clinical Leader Recognized as Fellow of the American Society of Clinical Oncology

Rutgers Cancer Institute of New Jersey Associate Chief of Urology and Urologic Oncology and Director of the Kidney Cancer Program Eric A. Singer, MD, MA, MS, FACS, has been named a Fellow of the American Society of Clinical Oncology (FASCO). This distinction honors members for their extraordinary volunteer service and dedication to the American Society of Clinical Oncology (ASCO).

*****UNDER EMBARGO UNTIL THURSDAY APRIL 22, 2021 AT 5PM ET*****

 

New Brunswick, N.J., April 22 2021 – Rutgers Cancer Institute of New Jersey Associate Chief of Urology and Urologic Oncology and Director of the Kidney Cancer Program Eric A. Singer, MD, MA, MS, FACS, has been named a Fellow of the American Society of Clinical Oncology (FASCO). This distinction honors members for their extraordinary volunteer service and dedication to the American Society of Clinical Oncology (ASCO).

ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer with the mission of conquering cancer through research, education, and promotion of the highest quality, equitable patient care. Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction is earned by only a limited number of active ASCO members through service to the organization and to the field of oncology.

Dr. Singer, an expert in the management of kidney cancer, has been a member of ASCO since 2003 and has served on the ethics committee, clinical practice guidelines committee, annual meeting education committee, and twice as a guideline chair. Singer works closely with his medical oncology and radiation oncology colleagues to offer patients an individualized and comprehensive cancer treatment plan that minimizes side effects and maximizes quality-of-life.

“As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is defined in part by its compassionate team of internationally recognized physicians and researchers driven by the mission to help individuals fight cancer. Dr. Singer has demonstrated his commitment to that mission through his dedication to our patients and contributions to the field of oncology,” shares Rutgers Cancer Institute Director Steven K. Libutti, MD, FACS, senior vice president, oncology services, RWJBarnabas Health. 

“As a member of ASCO, it has always been a pleasure collaborating with a wonderful team of international minds to support the mission of conquering cancer through research, education and promotion of the highest quality patient care,” notes Singer, who is also an associate professor of surgery and radiology at Rutgers Robert Wood Johnson Medical School. “I am proud to have earned the FASCO distinction and to be recognized by my peers as we all share the common goal of making a difference in the lives of people with cancer.”

Singer joined Rutgers Cancer Institute in 2012 after completing a clinical and research fellowship in the Urologic Oncology Branch of the National Cancer Institute.  He received his medical degree with honors in research from Georgetown University along with a master’s degree in bioethics. He performed his general surgery and urologic surgery training at the University of Rochester Medical Center where he also did a fellowship in clinical ethics. Singer has completed certificates in Clinical Research from the National Institutes of Health and the Harvard TH Chan School of Public Health and a master’s degree in clinical and translational science from Rutgers University.

In addition to ASCO, he is also a member of numerous professional organizations including the American Urological Association, Society of Urologic Oncology, American College of Surgeons and the American Society for Bioethics and Humanities.

About Rutgers Cancer Institute of New Jersey

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures.  Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.

 ###